Breast Cancer

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.

Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.

Although Keytruda did not improve overall survival when compared with chemotherapy, patients with a higher PD-L1 expression may derive a greater benefit with Keytruda, as shown with a longer median overall survival.

From a Baltimore restaurant owner traveling six hours to cook for a terminally ill customer to the death of a pioneer in breast cancer treatment, here’s what’s happening in the cancer landscape this week.

Data from a recent study demonstrates that patients with breast cancer — especially those who are younger, privately insured, of non-White race and lower-income — are more likely to file for bankruptcy than those without cancer.

Postponing tests or doctor visits during the pandemic may increase women’s risk of cancer.

Why do some survive cancer, while others don’t? And why do those who survive often feel the aches of survivor’s guilt? Here, a survivor shares how she learned to cope.

Increasing healthy eating habits and exercise is important in patients with breast cancer, according to an expert from Mass General Cancer Center.

Sara A. Hurvitz, M.D., reviews the history of HER2+ breast cancer and the progressive research that has been done in this disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, describes her experience learning about the surplus of treatment options and how she overcame her initial apprehension.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her initial impression of when she was diagnosed.

Sara A. Hurvitz, M.D., describes the subtypes, staging and grading of breast cancer.

Body image and body positivity are very important, especially after a life-changing surgery such as a mastectomy, writes a breast cancer survivor. Here, she offers fashion suggestions for “flatties” to feel their best.

Triple-negative breast cancer, which is found in 15%-20% of invasive breast cancers, is a challenge when it comes to treatment, but thanks to new drug approvals and therapy regimens, the treatment landscape has progressed in recent years, according to an expert.

Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.

Mindfulness practices have been associated with improved mental health outcomes in patients with cancer. Here, an expert shares tips on how patients can strengthen their “mindfulness muscle.”

With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.

In honor of International Women’s Day, CURE® compiled some recent news and updates in women’s cancers that patients, survivors and caregivers may have missed.

A breast cancer survivor who opted for a unilateral mastectomy advises people to look at all treatment and risk reduction options when first diagnosed with breast cancer so they can avoid any regrets years later.

View the full CURE Educated Patient Breast Cancer Summit on demand.

A roundup of some of the latest news and updates for patients with breast cancer from CURE®

Last week, the Food and Drug Administration (FDA) was scheduled to make a decision on whether or not they would approve oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The agency decided not to approve the regimen, and issued a complete response letter outlining why.